List of Excipients in Branded Drug NUBEQA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bayer HealthCare Pharmaceuticals Inc	NUBEQA	darolutamide	50419-395	ANHYDROUS DIBASIC CALCIUM PHOSPHATE	2042-06-17
Bayer HealthCare Pharmaceuticals Inc	NUBEQA	darolutamide	50419-395	CROSCARMELLOSE SODIUM	2042-06-17
Bayer HealthCare Pharmaceuticals Inc	NUBEQA	darolutamide	50419-395	LACTOSE MONOHYDRATE	2042-06-17
Bayer HealthCare Pharmaceuticals Inc	NUBEQA	darolutamide	50419-395	MAGNESIUM STEARATE	2042-06-17

NUBEQA Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

NUBEQA (darolutamide) is a high-value oral androgen-receptor inhibitor whose excipient strategy is commercially relevant because the product is dosed at 600 mg twice daily with food and is supplied as 300 mg film-coated tablets. The main opportunities are formulation optimization, lower-pill-burden presentations, qualified excipient supply, generic development, and manufacturing technologies that improve exposure while reducing dependence on food intake.

What is NUBEQA and how does its formulation affect excipient demand?

NUBEQA contains darolutamide, a nonsteroidal androgen-receptor inhibitor marketed by Bayer and developed with Orion. The FDA approved NUBEQA in 2019 for nonmetastatic castration-resistant prostate cancer and expanded the indication in 2022 for metastatic hormone-sensitive prostate cancer in combination with androgen-deprivation therapy and docetaxel. In 2023, FDA approved NUBEQA with androgen-deprivation therapy for metastatic hormone-sensitive prostate cancer in patients who are appropriate for combination treatment, including use without docetaxel in specified settings. The exact indication depends on the applicable FDA label version. (U.S. Food and Drug Administration [FDA], 2019, 2022, 2023)

The approved adult dose is 600 mg twice daily, administered as two 300 mg tablets per dose with food. The regimen requires four tablets per day. That dosing structure creates a commercial opening for higher-strength tablets, modified-release designs, or bioavailability-enhancing formulations that reduce tablet count.

What excipients are used in NUBEQA tablets?

The FDA-approved product is an immediate-release, film-coated tablet. Public labeling identifies conventional oral solid-dose excipients, including:

Formulation function	NUBEQA excipient class
Diluent and compression aid	Lactose monohydrate and microcrystalline cellulose
Binder	Hypromellose or related cellulose-based binder
Disintegrant	Croscarmellose sodium or a comparable superdisintegrant
Lubricant	Magnesium stearate
Surfactant or wetting agent	Sodium lauryl sulfate
Film coating	Hypromellose-based coating system
Coating modifiers	Polyethylene glycol, titanium dioxide, talc, and iron oxide pigments

The precise composition should be taken from the current FDA-approved prescribing information and product labeling before a development or litigation decision. Excipient concentrations, grade designations, manufacturing order, granulation conditions, and process controls are not fully disclosed in the prescribing information.

The formulation is commercially important for three reasons:

1. Darolutamide has limited aqueous solubility.
2. Exposure is materially affected by food.
3. The approved dose produces a high daily tablet burden.

Those attributes create room for excipient and process improvements even if the active ingredient is unchanged.

Why is food administration important for NUBEQA formulation strategy?

NUBEQA must be taken with food because food increases darolutamide exposure. The prescribing information reports that administration with food increases exposure compared with fasting conditions. The product therefore relies partly on meal-associated gastrointestinal conditions to achieve its intended pharmacokinetic profile. (FDA, 2023)

A formulation that reduces food dependence could have commercial value in several settings:

• Patients with poor appetite or cancer-related weight loss.
• Patients receiving chemotherapy and experiencing nausea.
• Patients taking multiple oral medicines on variable schedules.
• Hospital or specialty-pharmacy settings where administration timing is difficult.
• International markets where meal composition varies substantially.

Which excipient technologies could reduce food dependence?

Potential technologies include:

Technology	Potential commercial benefit	Development risk
Surfactant-based formulation	Improves wetting and dissolution	May cause gastrointestinal tolerability or stability issues
Lipid-based delivery system	Can mimic food-related solubilization	Requires control of oxidation, precipitation, and capsule or tablet compatibility
Amorphous solid dispersion	Raises apparent solubility	Risk of recrystallization and physical instability
Spray-dried dispersion	Enables polymer-based solubility enhancement	Requires specialized manufacturing and scale-up
Nanocrystal or micronized API	Increases surface area and dissolution rate	May not fully replicate food effects
Self-emulsifying delivery system	Improves dispersion in gastrointestinal fluid	Usually more difficult to convert into a robust tablet
Precipitation-inhibiting polymer	Maintains supersaturation after dissolution	Polymer selection can affect release and absorption

The strongest opportunity is a formulation that produces consistent exposure without requiring a high-fat or substantial meal. A company that demonstrates equivalent efficacy with less food dependence could pursue a product improvement strategy, a formulation patent, or a differentiated generic strategy.

What commercial opportunities exist for NUBEQA excipient suppliers?

Which excipients have the highest supply-chain opportunity?

NUBEQA is a large-volume oncology product with expanding use in prostate cancer. The most commercially relevant excipient categories are high-volume, compendial materials rather than highly specialized excipients.

Excipient category	Commercial opportunity	Supplier priority
Microcrystalline cellulose	Tablet-bulk and compressibility supply	High
Lactose monohydrate	Diluent supply and grade substitution	High
Superdisintegrants	Tablet breakup and dissolution control	High
Magnesium stearate	Lubrication and ejection performance	Medium
Sodium lauryl sulfate	Wetting and dissolution support	Medium
Hypromellose	Binder and coating supply	High
Polyethylene glycol	Film-coating plasticization	Medium
Pigments and opacifiers	Product identification and light protection	Low to medium

The highest-value supplier proposition is not simply low price. It is validated equivalence across particle-size distribution, moisture, bulk density, flow, compressibility, microbial quality, and elemental impurities. A grade change in lactose, cellulose, or a superdisintegrant can alter tablet hardness, disintegration, dissolution, and bioavailability.

Where can excipient manufacturers differentiate?

Excipient manufacturers can compete through:

• Dual-site manufacturing.
• Regulatory support packages for multiple jurisdictions.
• Low-peroxide and low-moisture grades.
• Consistent particle-size distributions.
• Direct compression grades.
• Nitrosamine risk assessments.
• Extractables and leachables data.
• Supply continuity during oncology-product demand increases.
• Technical assistance for scale-up and process validation.

For NUBEQA-type products, a supplier that can support Q1/Q2 excipient matching and comparative dissolution has greater value to generic applicants than a supplier offering only a pharmacopeial certificate.

Can a higher-strength NUBEQA tablet create a commercial opportunity?

A higher-strength tablet could reduce the current four-tablet daily burden. Options include a 600 mg tablet taken twice daily or a formulation with higher drug loading and improved dissolution. A 600 mg strength would require assessment of:

• Tablet size and swallowability.
• Dose uniformity.
• Mechanical strength.
• Disintegration and dissolution.
• Food-effect comparability.
• Pharmacokinetic equivalence.
• Dose flexibility for renal or hepatic impairment.
• Risk of medication error between 300 mg and 600 mg presentations.

A higher-strength product could be developed by the originator as a lifecycle product or by a generic applicant as a differentiated dosage form. The commercial value would depend on regulatory pathway, intellectual-property protection, reimbursement treatment, and whether prescribers view pill burden as a meaningful adherence barrier.

The principal formulation challenge is achieving a high drug load without compromising tablet manufacturability. Increasing the proportion of darolutamide can reduce the relative amount of diluent and disintegrant. The resulting tablet may have slower disintegration, poor tensile strength, or increased sensitivity to lubrication time.

What formulation patents may protect NUBEQA?

The relevant intellectual-property categories include:

1. Darolutamide composition-of-matter patents.
2. Pharmaceutical compositions containing darolutamide.
3. Solid-state forms, salts, solvates, or polymorphs.
4. Tablet and film-coating formulations.
5. Methods of treating prostate cancer.
6. Combination treatment with androgen-deprivation therapy.
7. Use with docetaxel.
8. Manufacturing processes and crystallization methods.
9. Dosage regimens and patient-selection methods.

Excipient-specific protection is most likely to arise through a broader pharmaceutical-composition claim rather than a claim directed solely to a commodity excipient. A formulation patent may define the active ingredient, excipient classes, concentration ranges, dissolution profile, particle size, or pharmacokinetic parameters.

A competitor should distinguish between:

• A patent that claims darolutamide itself.
• A patent that claims a specific formulation.
• A patent that claims a method of use.
• A patent that claims a manufacturing process.
• A patent listed in the FDA Orange Book.
• A patent that is commercially relevant but not listed for regulatory purposes.

The Orange Book determines which patents an ANDA applicant must address through a Paragraph IV certification. Method-of-use patents may be addressed through a section viii statement if the generic label can omit the patented indication. Formulation and composition patents generally create broader exposure because they may cover the product regardless of indication.

When does NUBEQA lose regulatory exclusivity?

NUBEQA received FDA approval in 2019. Small-molecule new chemical entity exclusivity generally lasts five years from approval, subject to statutory exceptions. That period is separate from patent protection and does not determine the final date for generic launch.

Regulatory or commercial milestone	Timing
Initial FDA approval	July 2019
Initial indication	Nonmetastatic castration-resistant prostate cancer
Major label expansion	Metastatic hormone-sensitive prostate cancer
Current dosing framework	600 mg twice daily with food
Regulatory generic pathway	ANDA, not biosimilar
Key regulatory barrier	Orange Book patent certifications and bioequivalence

NUBEQA is a small-molecule drug. Biosimilar risk does not apply. The relevant competitors are generic darolutamide products, alternative androgen-receptor inhibitors, and other prostate-cancer regimens.

Exact generic-entry timing depends on the current Orange Book patent listings, patent-term adjustments, pediatric exclusivity, any court decisions, and settlement agreements. Patent expiry dates should be assessed patent by patent rather than inferred from the 2019 approval date.

What Paragraph IV challenges could affect NUBEQA?

An ANDA applicant may submit a Paragraph IV certification asserting that an Orange Book-listed patent is invalid, unenforceable, or not infringed. A Paragraph IV notice can trigger patent litigation and a statutory 30-month stay of FDA approval, subject to the governing facts and litigation timeline.

Potential Paragraph IV targets include:

• Composition-of-matter claims.
• Darolutamide formulation claims.
• Solid-state or polymorph claims.
• Method-of-use claims.
• Combination-treatment claims.

The commercial attractiveness of a Paragraph IV filing depends on the expected market size, remaining patent life, ease of designing around formulation claims, and the strength of the originator’s evidence linking the listed patent to the marketed product.

A generic company may choose a conservative route by matching the reference formulation closely. A challenger seeking earlier launch may instead develop a non-infringing excipient system, provided it can establish bioequivalence without relying on protected formulation features.

How strong is the NUBEQA patent estate from an excipient perspective?

The formulation estate is potentially stronger when claims connect excipient composition to a measurable performance result. Examples include:

• A defined dissolution profile.
• A specified exposure range.
• A reduced food effect.
• A controlled particle-size distribution.
• A specific solid-state form maintained in the tablet.
• A stability profile under accelerated conditions.
• A narrow excipient ratio that produces a technical effect.

Claims directed only to conventional excipients in ordinary amounts are generally easier to challenge or design around than claims tied to a defined pharmacokinetic or dissolution outcome. Process claims can still create manufacturing barriers, but they may be avoided through an alternative granulation, drying, coating, or compression process.

The most defensible formulation strategy would combine composition claims with process controls and performance specifications. That structure raises the cost of generic substitution because a competitor must solve both the formulation and the analytical equivalence problem.

How does NUBEQA compare with competing prostate-cancer drugs?

Product	Active ingredient	Form	Key formulation issue	Generic or biosimilar risk
NUBEQA	Darolutamide	Immediate-release tablet	Food-dependent exposure and high tablet count	Generic
XTANDI	Enzalutamide	Capsules and tablets	Solubility, dose strength, formulation differences	Generic
ERLEADA	Apalutamide	Tablet	High-dose solid oral formulation	Generic
ORGOVYX	Relugolix	Tablet	Oral absorption and chronic dosing	Generic
Firmagon	Degarelix	Injectable	Reconstitution and peptide delivery	Biosimilar-style competition is less direct
Pluvicto	Lutetium-177 vipivotide tetraxetan	Radioligand therapy	Radioactive manufacturing and distribution	Not a conventional generic-tablet market

NUBEQA's differentiation is its androgen-receptor mechanism, clinical positioning, combination-treatment use, and safety profile relative to some competing androgen-receptor pathway inhibitors. Its excipient opportunity is less about creating a novel dosage form than about improving adherence, reducing food dependence, and simplifying administration.

What manufacturing and IP barriers affect NUBEQA generic development?

Generic developers face several barriers:

• Darolutamide API supply and impurity control.
• Reproduction of dissolution performance across multiple pH conditions.
• Food-effect assessment.
• High-dose tablet manufacture.
• Control of polymorphic or solid-state behavior.
• Demonstration of bioequivalence under fed and fasted conditions.
• Patent claims covering composition, use, or process.
• Potential litigation following a Paragraph IV filing.
• Regulatory differences across the United States, Europe, Japan, and emerging markets.

Excipient selection can lower development risk. A formulation that uses widely available compendial excipients is easier to source and defend in regulatory filings. A formulation that depends on a proprietary polymer, specialized lipid, or single-source grade may improve performance but create supply and freedom-to-operate risks.

What are the revenue and licensing opportunities?

NUBEQA has become a major Bayer oncology product as its prostate-cancer indications expanded. Bayer's annual reports identify NUBEQA as a growth product within the pharmaceutical portfolio. (Bayer AG, 2024)

Commercial opportunities include:

• Supplying qualified excipients to Bayer or its contract manufacturers.
• Licensing bioavailability-enhancing formulation technology.
• Developing a 600 mg tablet or lower-pill-burden product.
• Supplying generic-grade excipients to future ANDA applicants.
• Licensing non-infringing formulation platforms.
• Providing analytical services for dissolution and food-effect studies.
• Developing regional manufacturing capacity for darolutamide tablets.
• Supporting combination-packaging or adherence-oriented packaging.

The largest value opportunity is likely a formulation platform that reduces food dependence or tablet burden while preserving exposure. Commodity excipient sales offer larger volume but lower margins. Proprietary formulation technology offers higher margins but faces patent, clinical, and regulatory risk.

What is the likely generic launch scenario for NUBEQA?

A first-wave generic launch would most likely use the current immediate-release tablet architecture and conventional excipients. The applicant would prioritize:

1. Q1/Q2 similarity where practical.
2. Fed and fasted bioequivalence.
3. Comparative dissolution.
4. A simple manufacturing process.
5. Avoidance of unnecessary formulation changes.
6. Paragraph IV certification against relevant Orange Book patents.

A differentiated generic could use a different excipient system if it achieves bioequivalence and avoids infringement. A higher-strength tablet would offer a commercial advantage but could require additional clinical or pharmacokinetic work and face greater formulation-patent exposure.

The competitive market will likely develop in stages: first, litigation-driven entry by one or more challengers; second, limited competition after settlement or court resolution; and third, price erosion as multiple manufacturers enter.

Key Takeaways

• NUBEQA uses a conventional film-coated immediate-release tablet, but darolutamide's food-dependent exposure creates a meaningful formulation opportunity.
• The approved 600 mg twice-daily regimen requires four 300 mg tablets per day, supporting interest in higher-strength or higher-bioavailability products.
• The most valuable excipient technologies are those that reduce food dependence, improve dissolution, stabilize amorphous material, or support high drug loading.
• Excipient suppliers can compete through grade consistency, dual sourcing, regulatory documentation, and control of critical material attributes.
• NUBEQA faces generic rather than biosimilar competition.
• Paragraph IV risk depends on the current Orange Book listings, patent claims, litigation outcomes, and any settlement terms.
• A formulation patent is stronger when it ties excipient composition to dissolution, exposure, stability, or reduced food effect.
• The best licensing targets are enabling formulations that improve adherence without requiring a new mechanism or a major change in clinical use.

FAQs

Can NUBEQA be formulated as a once-daily tablet?

A once-daily formulation would require sustained exposure over 24 hours and successful pharmacokinetic bridging. The current approved regimen is 600 mg twice daily, so once-daily development would be a new formulation and regulatory program rather than a simple strength change.

Is sodium lauryl sulfate essential to NUBEQA performance?

Public labeling identifies excipient components but does not establish that any individual surfactant is indispensable. A generic or lifecycle developer could evaluate alternative wetting agents, provided dissolution, stability, tolerability, and bioequivalence remain acceptable.

Could a lipid formulation replace the food requirement for NUBEQA?

A lipid-based formulation could potentially reduce food dependence by improving solubilization in the gastrointestinal tract. It would require proof of chemical stability, manufacturability, bioequivalence, and consistent exposure under fed and fasted conditions.

Are NUBEQA excipient patents likely to block all generic formulations?

No. A formulation patent may cover a defined composition, process, solid-state form, or performance profile. A generic applicant may avoid infringement through an alternative excipient system or manufacturing process, subject to bioequivalence and regulatory requirements.

What is the most attractive commercial opportunity around NUBEQA excipients?

The highest-value opportunity is a validated formulation that reduces food dependence or tablet burden while maintaining darolutamide exposure. The most scalable lower-risk opportunity is qualified supply of direct-compression diluents, disintegrants, binders, lubricants, and film-coating materials.

References

Bayer AG. (2024). Annual report 2024. Bayer AG.

U.S. Food and Drug Administration. (2019). FDA approves darolutamide for non-metastatic castration-resistant prostate cancer. U.S. Department of Health and Human Services.

U.S. Food and Drug Administration. (2022). FDA approves darolutamide with docetaxel for metastatic hormone-sensitive prostate cancer. U.S. Department of Health and Human Services.

U.S. Food and Drug Administration. (2023). NUBEQA (darolutamide) prescribing information. U.S. Department of Health and Human Services.